PMID- 33017043
OWN - NLM
STAT- MEDLINE
DCOM- 20210105
LR  - 20210105
IS  - 1365-4632 (Electronic)
IS  - 0011-9059 (Linking)
VI  - 60
IP  - 1
DP  - 2021 Jan
TI  - Prevalence of antimitochondrial antibodies in subacute cutaneous lupus 
      erythematosus.
PG  - 88-92
LID - 10.1111/ijd.15225 [doi]
AB  - BACKGROUND: In approximately 13% of systemic lupus erythematosus (SLE) patients, 
      a hallmark of primary biliary cirrhosis (PBC) can be detected: antimitochondrial 
      M2 antibodies (AMA-M2). It has not been determined if the presence of AMA-M2 in 
      SLE patients results in a higher risk of PBC in comparison to those with AMA but 
      no SLE. Until now, there have been no such analyses among individuals with 
      subacute cutaneous lupus erythematosus (SCLE). METHODS: To assess the 
      seropositivity rates for AMA-M2 and autoantibodies associated with autoimmune 
      hepatitis in patients with newly diagnosed SCLE and to determine the coexistence 
      and risk of development of autoimmune liver disease in these patients within 
      1 year of follow-up, data from 33 patients with newly diagnosed SCLE were 
      analyzed. RESULTS: AMA-M2 was found in 20% of SCLE patients. Patients from the 
      AMA-M2-positive group were characterized by significantly higher levels of 
      cholestatic liver enzymes when compared to those without AMA-M2 (P < 0.05). After 
      introducing therapy with hydroxychloroquine and prednisone, the levels of 
      hepatocellular enzymes increased significantly only in AMA-M2 positive patients 
      (P < 0.05). CONCLUSIONS: A high prevalence of AMA-M2 was found in patients with 
      SCLE. Patients with SCLE and AMA-M2 had significantly higher values of 
      cholestatic enzymes than patients without AMA. Newly diagnosed patients with SCLE 
      should be screened for the presence of AMA and should be clinically followed up. 
      Avoiding drugs with potential liver toxicity should be recommended in patients 
      with SCLE and AMA.
CI  - (c) 2020 the International Society of Dermatology.
FAU - Pelka, Karolina
AU  - Pelka K
AD  - Department of Dermatology, Jagiellonian University Medical College, Cracow, 
      Poland.
FAU - Stec-Polak, Magdalena
AU  - Stec-Polak M
AD  - Department of Dermatology, Jagiellonian University Medical College, Cracow, 
      Poland.
FAU - Wojas-Pelc, Anna
AU  - Wojas-Pelc A
AD  - Department of Dermatology, Jagiellonian University Medical College, Cracow, 
      Poland.
FAU - Pastuszczak, Maciej
AU  - Pastuszczak M
AD  - Department of Dermatology, Jagiellonian University Medical College, Cracow, 
      Poland.
LA  - eng
PT  - Journal Article
DEP - 20201005
PL  - England
TA  - Int J Dermatol
JT  - International journal of dermatology
JID - 0243704
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Autoantibodies)
RN  - 0 (anti-liver kidney microsome antibody)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - EC 2.3.2.2 (gamma-Glutamyltransferase)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alanine Transaminase/blood
MH  - Alkaline Phosphatase/blood
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Antirheumatic Agents/therapeutic use
MH  - Aspartate Aminotransferases/blood
MH  - Autoantibodies/*blood
MH  - Comorbidity
MH  - Disease Progression
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hepatitis, Autoimmune/blood/*epidemiology
MH  - Humans
MH  - Hydroxychloroquine/therapeutic use
MH  - Liver Cirrhosis, Biliary/blood/*epidemiology
MH  - Lupus Erythematosus, Cutaneous/*blood/drug therapy/*epidemiology
MH  - Male
MH  - Middle Aged
MH  - Mitochondria/*immunology
MH  - Muscle, Smooth/immunology
MH  - Poland/epidemiology
MH  - Prednisone/therapeutic use
MH  - Prevalence
MH  - Risk Factors
MH  - Seroepidemiologic Studies
MH  - gamma-Glutamyltransferase/blood
EDAT- 2020/10/06 06:00
MHDA- 2021/01/06 06:00
CRDT- 2020/10/05 12:10
PHST- 2020/04/09 00:00 [received]
PHST- 2020/08/28 00:00 [revised]
PHST- 2020/09/04 00:00 [accepted]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2021/01/06 06:00 [medline]
PHST- 2020/10/05 12:10 [entrez]
AID - 10.1111/ijd.15225 [doi]
PST - ppublish
SO  - Int J Dermatol. 2021 Jan;60(1):88-92. doi: 10.1111/ijd.15225. Epub 2020 Oct 5.